America Wants to Make More Generic Drugs. India Shows Why That’s Hard.

A successful policy framework that materially shifts generic drug manufacturing capacity to the U.S. would likely ease long-term supply-chain risk premiums in pharma and reduce pricing pressure on domestic manufacturers, though the transition costs and timeline would initially weigh on margins.

If onshoring efforts remain rhetorical or face regulatory and cost barriers without major policy intervention, generic drug supply chains would continue to rely on India and other offshore producers, leaving concentration risk and cost-competitiveness dynamics largely unchanged.

Protectionist measures or tariffs aimed at forcing domestic generic production without addressing underlying cost structures could disrupt supply chains, raise generic drug prices, and create friction with India—outcomes that would likely pressure healthcare cost expectations and generic-dependent equity valuations.